F Dol
Overview
Explore the profile of F Dol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dol F, Martin G, Staels B, Mares A, Cazaubon C, Nisato D, et al.
J Cardiovasc Pharmacol
. 2001 Aug;
38(3):395-405.
PMID: 11486244
Recent data suggest that angiotensin II AT1 receptor antagonists may be beneficial in the treatment of atherosclerosis. To clarify how AT1 receptor antagonists reduce atherosclerosis, the effect of irbesartan on...
2.
Hainaud P, Bonneau M, Pignaud G, Bal Dit Sollier C, Andre P, Hadjiisky P, et al.
Atherosclerosis
. 2001 Feb;
154(2):301-8.
PMID: 11166762
We studied the effect of SR33805, a calcium channel blocker, in vitro on the proliferation of vascular smooth muscle cells (SMC) stimulated by foetal calf serum, basic fibroblast growth factor...
3.
Herault J, Dol F, Gaich C, Bernat A, Herbert J
Thromb Haemost
. 1999 Jul;
81(6):957-60.
PMID: 10404775
Clopidogrel (25 mg/kg, p.o.), a potent and selective inhibitor of ADP-induced platelet aggregation, significantly inhibited, in the presence of platelets, ex vivo thrombin generation triggered by low concentrations of tissue...
4.
Herbert J, Dol F, Bernat A, Falotico R, Lale A, Savi P
Thromb Haemost
. 1998 Oct;
80(3):512-8.
PMID: 9759636
It is unknown whether the addition of aspirin might increase both the efficacy and the potency of clopidogrel, a potent and selective ADP blocker. For that purpose, the efficacy of...
5.
Herbert J, Bono F, Herault J, Avril C, Dol F, Mares A, et al.
J Clin Invest
. 1998 Apr;
101(5):993-1000.
PMID: 9486969
The binding of 125I-factor Xa to human aortic smooth muscle cell (SMC) monolayers was studied. At 4 degreesC, 125I-factor Xa bound to a single class of binding sites with a...
6.
Schaeffer P, Mares A, Dol F, Bono F, Herbert J
Circ Res
. 1997 Nov;
81(5):824-8.
PMID: 9351456
The relaxing effect of coagulation factor Xa on phenylephrine-contracted rat aortic rings was compared with the effect of thrombin and trypsin. All three proteases induced a dose-dependent relaxation in the...
7.
Herbert J, Guy A, Lamarche I, Mares A, Savi P, Dol F
J Cell Physiol
. 1997 Feb;
170(2):106-14.
PMID: 9009139
Thrombin is a multifunctional serine protease with central functions in hemostasis, but demonstration of its role in the initiation and maintenance of cell proliferation which occurs following vascular injury is...
8.
Dol F, Mares A, Herbert J
Blood Coagul Fibrinolysis
. 1996 Nov;
7(8):772-8.
PMID: 9034557
The effect of simvastatin, a potent inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) was evaluated in an experimental model of myointimal hyperplasia in cholesterol-fed rabbits. Myointimal hyperplasia was...
9.
Herbert J, Bernat A, Dol F, Herault J, Crepon B, Lormeau J
J Pharmacol Exp Ther
. 1996 Mar;
276(3):1030-8.
PMID: 8786532
DX 9065A is the first member of a newly developed series of synthetic and selective inhibitors of factor Xa. DX 9065A inhibited in a dose-dependent manner human factor Xa with...
10.
Dol F, Schaeffer P, Lamarche I, Mares A, Chatelain P, Herbert J
Eur J Pharmacol
. 1995 Jul;
280(2):135-42.
PMID: 7589177
The possible activity of SR 33805 ([[N-[dimethoxy-3,4-phenethyl]-N- methylamino-propoxyl]-4-benzenesulfonyl]-2-isopropyl-3-methyl-1-in dole), a novel Ca2+ channel blocker, in early atherogenesis was investigated. In vitro, SR 33805 strongly inhibited fetal calf serum-induced proliferation of...